Free Trial
→ My public warning after 55 years of watching the markets (From Weiss Ratings) (Ad)tc pixel
NASDAQ:PEPG

PepGen Q2 2025 Earnings Results & Report

PepGen logo
$5.44 +0.83 (+17.90%)
As of 03:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

PepGen beat analyst earnings expectations in its Q2 2025 results, released August 7, 2025. The company reported EPS of -$0.70 versus the -$0.85 consensus estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

PepGen EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.85
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

PepGen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

PepGen's Q2 2025 Press ReleasePress Release
(8-K)
PepGen's Q2 2025 Quarterly reportQuarterly report
(10-Q)

PepGen Q2 2025 Earnings FAQ

PepGen (NASDAQ:PEPG) reported earnings of -$0.70 per share for Q2 2025, beating the consensus estimate of -$0.85. The report was announced on Thursday, August 7, 2025.

PepGen Earnings Headlines

PepGen’s stock skyrockets on record-breaking DM1 trial data
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/pepgen-stock-skyrockets-record-breaking-181947497.html
PepGen Stock Soars 129% Despite Wider Q3 Loss
November 11 at 4:34 AM  |  rttnews.comhttps://www.rttnews.com/3712675/pepgen-stock-soars-129-despite-wider-q3-loss.aspx
To Washington, you're rich now
Washington just won on a promise to tax the rich. But the largest untaxed pool of money in America isn't on a yacht, it's in 401(k)s and IRAs. With a $2 trillion deficit, a new Congress could change contribution limits, timing rules, or what counts as too much, without ever raising your tax rate. Bishop Gold Group's free 2026 Gold IRA Guide shows what you can hold in your own name, under the same tax treatment you have today.tc pixel
November 11 at 1:00 AM  |  Bishop Gold Group (Ad)
PepGen stock soars over 100% on positive Phase 2 trial data for DM1 drug
November 11 at 4:34 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pepgen-stock-soars-over-100-140645055.html
Stock Traders Purchase Large Volume of Put Options on PepGen (NASDAQ:PEPG)
November 11 at 4:31 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31192545
PepGen reports phase 2 myotonic dystrophy trial results and $104.8 million cash position
November 10 at 11:34 PM  |  msn.comhttps://www.msn.com/en-us/money/other/pepgen-reports-phase-2-myotonic-dystrophy-trial-results-and-104-8-million-cash-position/ar-AA2h9Jak
See More PepGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email.

About PepGen

PepGen (NASDAQ:PEPG) Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue. The company’s research and development efforts have focused primarily on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

Its lead programs include PGN-EDO51, an exon-skipping therapy being developed for a subset of patients with DMD who may benefit from exon 51 skipping, and PGN-EDODM1, an investigational treatment designed to address the underlying RNA-processing defects associated with DM1. PepGen is based in the United States and is advancing these programs through clinical development. James McNally serves as the company’s president and chief executive officer.

View PepGen Profile
Earnings Tools